An innovative pyroptosis-related long-noncoding-RNA signature predicts the prognosis of gastric cancer via affecting immune cell infiltration landscape

Abstract

Background: Gastric cancer (GC) is a worldwide popular malignant tumor. However, the survival rate of advanced GC remains low. Pyroptosis and long non-coding RNAs (lncRNAs) are important in cancer progression. Thus, we aimed to find out a pyroptosis-related lncRNAs (PRLs) signature and use it to build a practical risk model with the purpose to predict the prognosis of patients with GC.Methods: Univariate Cox regression analysis was used to identify PRLs linked to GC patient’s prognosis. Subsequently, to construct a PRLs signature, the least absolute shrinkage and selection operator regression, and multivariate Cox regression analysis were used. Kaplan–Meier analysis, principal component analysis, and receiver operating characteristic curve analysis were performed to assess our novel lncRNA signature. The correlation between risk signature and clinicopathological features was also examined. Finally, the relationship of pyroptosis and immune cells were evaluated through the CIBERSORT tool and single-sample lncRNA set enrichment analysis (ssGSEA).Results: A PRLs signature comprising eight lncRNAs was discerned as a self-determining predictor of prognosis. GC patients were sub-divided into high-risk and low-risk groups via this risk-model. Stratified analysis of different clinical factors also displayed that the PRLs signature was a good prognosis factor. According to the risk score and clinical characteristics, a nomogram was established. Moreover, the difference between the groups is significance in immune cells and immune pathways.Conclusion: This study established an effective prognostic signature consist of eight PRLs in GC, and constructed an efficient nomogram model. Further, the PRLs correlated with immune cells and immune pathways.

Natural products targeting signaling pathways associated with regulated cell death in gastric cancer: Recent advances and perspectives

“…LncRNA ADAMTS9‐AS2, a verified tumor suppressor, was revealed to promote NLRP3 mediated pyroptosis in GC cells, as well as enhancing cisplatin sensitivity (Ren et al, 2020). Similarly, a number of non‐coding RNAs associated with pyroptosis have been explored to establish effective predictive models of GC, which contribute to the immune and pharmacological landscape of GC microenvironments (Guo et al, 2022; Xiong et al, 2022; Yin, Che, et al, 2022a). Consequently, induction of activation of cellular pyroptosis is a promising pathway for GC treatment.…”